AAS
RETA

Ameritas Advisory Services’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Ameritas Advisory Services’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,908
Closed -$355K – 2690
2023
Q1 		$355K Buy
+3,908
New +$229K 0.02% 593

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Advisory Services's RETA Position: Q2 2023 in Review

Ameritas Advisory Services sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2023, closing a stake of 3,908 shares — an estimated $355K sold.

Ameritas Advisory Services first reported a position in RETA in Q1 2023 and held it in 1 quarter. The position peaked at $355K in Q1 2023. 214 funds tracked by Wall St. Rank hold RETA as of Q2 2023.

  • Ameritas Advisory Services reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
  • Ameritas Advisory Services sold 3,908 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2023, an estimated $355K.
  • Ameritas Advisory Services first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2023 and held it in 1 quarter.
  • Ameritas Advisory Services's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $355K in Q1 2023.
  • 214 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2023.

Based on Ameritas Advisory Services's 13F filing for Q2 2023, filed 25 Jul 2023.